Benchimol-Barbosa PR, Barbosa-Filho J. Comment on the article by Vázquez and Márquez-Garcia. High-risk vs. low-risk for thrombo-embolic events: Who are in the intermediate-risk group? What should be done then?
Int J Cardiol 2008;
124:358-9; author reply 360-1. [PMID:
17400310 DOI:
10.1016/j.ijcard.2007.01.056]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2006] [Accepted: 01/02/2007] [Indexed: 11/22/2022]
Abstract
Although high risk and low risk profile for thrombo-embolic events have been extensively and intensively investigated in multi-centre trials and described in detail in atrial fibrillation guidelines, the management of those at otherwise intermediate risk is still a 'no-one's zone'. Individual risk profile is mandatory to identify those who will benefit of anti-coagulation therapy and large-scale clinical trials are still awaited to define efficacy and efficiency profile in intermediate-risk group.
Collapse